for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

ROG.S

Latest Trade

290.25CHF

Change

2.05(+0.71%)

Volume

1,045,040

Today's Range

288.00

 - 

290.90

52 Week Range

229.20

 - 

291.45

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
288.20
Open
289.25
Volume
1,045,040
3M AVG Volume
39.47
Today's High
290.90
Today's Low
288.00
52 Week High
291.45
52 Week Low
229.20
Shares Out (MIL)
856.06
Market Cap (MIL)
248,212.20
Forward P/E
14.99
Dividend (Yield %)
2.88

Next Event

Q3 2019 Roche Holding AG Corporate Sales Release

Latest Developments

More

Roche Says Phase 3 Study Shows Mabthera/Rituxan Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

Roche: Tecentriq Reduced Risk Of Disease Worsening Compared With Chemotherapy Alone

FDA Approves Genentech's Rituxan (Rituximab) In Children With Two Rare Blood Vessel Disorders

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding Ltd.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

2.36 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

50.6K

2017

53.3K

2018

56.8K

2019(E)

61.2K
EPS (CHF)

2016

14.530

2017

15.340

2018

18.140

2019(E)

19.223
Price To Earnings (TTM)
21.11
Price To Sales (TTM)
4.19
Price To Book (MRQ)
8.79
Price To Cash Flow (TTM)
15.40
Total Debt To Equity (MRQ)
69.75
LT Debt To Equity (MRQ)
54.88
Return on Investment (TTM)
23.03
Return on Equity (TTM)
15.43

Latest News

Latest News

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche taps Lilly executive Garraway as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche taps Eli Lilly executive as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

Roche prices personalized cancer treatment at about $204,560 annually

Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday.

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.

Roche says test showed Tecentriq helped vs bladder cancer

Roche Holding said its Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer, the Swiss pharma company said on Monday.

Roche says test showed Tecentriq helped bladder cancer

Roche Holding said its Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer, the Swiss pharma company said on Monday.

Pfizer's Avastin biosimilar wins FDA approval

Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin.

Roche's combo lymphoma treatment wins U.S. FDA approval

(This June 10 story deletes paragraph 9 to clarify that retreatment with Polivy has not been studied.)

Roche's combo lymphoma treatment wins FDA's accelerated approval

The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday

Roche sees no Brexit interruption for patients

Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In...

Roche says $4.3 billion Spark offer still on track for June completion

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

Roche extends Spark offer after getting 29 pct in tender

Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

U.S. FDA approves Roche's small cell lung cancer treatment

Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

Roche 'steps up' for gene therapy with $4.3 bln Spark bet

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to "step up", Chief Executive Severin Schwan said on Monday.

Roche nearing $5 billion deal to acquire Spark Therapeutics: WSJ

Swiss drugmaker Roche Holding AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Roche nearing $5 billion deal to acquire Spark Therapeutics -WSJ

Swiss drugmaker Roche Holding AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Roche CEO: Switzerland should enter framework agreement with EU over bilateral ties

Roche holding ag ceo says confident that roche is prepared for brexit scenarios Roche holding ag drug chief says flu season has been mild, so far, keeping sales of flu drugs in check Roche holding ag ceo says has invested lots of money in alzheimer's research, must accept...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up